<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195750</url>
  </required_header>
  <id_info>
    <org_study_id>6482-005</org_study_id>
    <secondary_id>2019-003444-72</secondary_id>
    <secondary_id>MK-6482</secondary_id>
    <secondary_id>205262</secondary_id>
    <nct_id>NCT04195750</nct_id>
  </id_info>
  <brief_title>A Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)</brief_title>
  <official_title>An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare MK-6482 to everolimus with respect to
      progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1
      (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare
      everolimus with respect to overall survival (OS). The hypothesis is that MK-6482 is superior
      to everolimus with respect to PFS and OS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2020</start_date>
  <completion_date type="Anticipated">September 17, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 17, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</measure>
    <time_frame>Up to approximately 47 months</time_frame>
    <description>PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review will be presented</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 47 months</time_frame>
    <description>Time from randomization to death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</measure>
    <time_frame>Up to approximately 47 months</time_frame>
    <description>ORR is defined as the percentage of participants who have a complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</measure>
    <time_frame>Up to approximately 47 months</time_frame>
    <description>For participants who demonstrate a confirmed complete response (CR: Disappearance of all target lesions) or confirmed partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death. The DOR as assessed by blinded independent central review will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience One or More Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 47 months</time_frame>
    <description>An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 47 months</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The number of participants who discontinue study treatment due to an AE will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in Health-Related Quality-of-Life (HRQoL) Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 29 and 30 Score</measure>
    <time_frame>Up to approximately 47 months</time_frame>
    <description>Time to Deterioration (TTD) is defined as the time from baseline to the first onset of a ≥10-point negative change (decrease) from baseline in global health status (Item 29) &amp; quality of life (Item 30) combined score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in global health status and quality of life combined score, will be presented. A longer TTD indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in Physical Functioning Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 1- 5 Score</measure>
    <time_frame>Up to approximately 47 months</time_frame>
    <description>TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline in physical functioning (EORTC QLQ-C30 Items 1-5) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from Baseline in physical functioning score, will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in Disease Symptoms Using the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms (FKSI-DRS) Items 1-9 Score</measure>
    <time_frame>Up to approximately 47 months</time_frame>
    <description>The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer over the previous 7 days. Responses are scored on a 5-point scale (0=Not at all to 4=Very much) and summed to generate an index symptom score. These scores can range from 0 to 36, with a higher score indicating more favorable kidney cancer symptom status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health-Related Quality-of-Life (HRQoL) Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 29 and 30 Score</measure>
    <time_frame>Baseline (Day 1) and up to approximately 47 months</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses for global health status (Item 29) &amp; quality of life (Item 30) are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 scores will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physical Functioning Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 1- 5 Score</measure>
    <time_frame>Baseline (Day 1) and up to approximately 47 months</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Symptoms Using the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms (FKSI-DRS) Items 1-9 Score</measure>
    <time_frame>Baseline (Day 1) and up to approximately 47 months</time_frame>
    <description>The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer over the previous 7 days. Responses are scored on a 5-point scale (0=Not at all to 4=Very much) and summed to generate an index symptom score. These scores can range from 0 to 36, with a higher score indicating more favorable kidney cancer symptom status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in European Quality of Life 5 Dimensions, 5-level Questionnaire (EuroQoL EQ-5D-5L) Health Utility Score</measure>
    <time_frame>Baseline (Day 1) and up to approximately 47 months</time_frame>
    <description>The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/ depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty, which are coded on a scale from 1 (no problems) to 5 (extreme problems). The participant is also asked to indicate his/her current health state by selecting the most appropriate level on a visual analog scale from 0 to 100, with 0 being the worst imaginable health state.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">736</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <arm_group>
    <arm_group_label>MK-6482</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 120 mg of MK-6482 orally once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive 10 mg of Everolimus orally once daily (QD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-6482</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>MK-6482</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Everolimus</arm_group_label>
    <other_name>Afinitor</other_name>
    <other_name>Afinitor DISPERZ</other_name>
    <other_name>Zortress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has unresectable, locally advanced or metastatic clear cell renal cell carcinoma (RCC)

          -  Has had disease progression on or after having received systemic treatment for locally
             advanced or metastatic RCC with both Programmed cell death 1 ligand 1 (PD-1/L1)
             checkpoint inhibitor and a vascular endothelial growth factor - tyrosine kinase
             inhibitor (VEGF-TKI) in sequence or in combination.

          -  Has received no more than 3 prior systemic regimens for locally advanced or metastatic
             RCC.

          -  A male participant is eligible to participate if he is abstinent from heterosexual
             intercourse or agrees to use contraception during the intervention period and for at
             least 5 days after the last dose of study intervention

          -  A female participant is eligible to participate if she is not pregnant, not
             breastfeeding, and at least 1 of the following conditions applies: Not a (woman of
             childbearing potential) WOCBP OR A WOCBP who agrees to follow the contraceptive
             guidance during the intervention period and for at least 30 days after the last dose
             of study intervention for those randomized to MK-6482 and for at least 8 weeks after
             the last dose of study intervention for those randomized to everolimus.

          -  The participant (or legally acceptable representative if applicable) provides written
             informed consent for the study.

          -  Has adequate organ function

        Exclusion Criteria:

          -  Has a known additional malignancy that is progressing or has required active treatment
             within the past 3 years. (Participants with basal cell carcinoma of the skin, squamous
             cell carcinoma of the skin, or carcinoma in situ [e.g., breast carcinoma, cervical
             cancer in situ] that have undergone potentially curative therapy are not excluded.)

          -  Has known central nervous system (CNS) metastases and/or carcinomatous meningitis.
             (Participants with previously treated brain metastases may participate provided they
             are radiologically stable for at least 4 weeks (28 days) by repeat imaging.)

          -  Has clinically significant cardiac disease, including unstable angina, acute
             myocardial infarction within 6 months from Day 1 of study drug administration, or New
             York Heart Association Class III or IV congestive heart failure. (Medically controlled
             arrhythmia stable on medication is permitted.)

          -  Has poorly controlled hypertension defined as systolic blood pressure (SBP) ≥150 mm Hg
             and/or diastolic blood pressure (DBP) ≥90 mm Hg.

          -  Has moderate to severe hepatic impairment (Child-Pugh B or C).

          -  Has a known psychiatric or substance abuse disorder that would interfere with
             cooperation with the requirements of the study.

          -  Is unable to swallow orally administered medication or has a gastrointestinal disorder
             affecting absorption (e.g., gastrectomy, partial bowel obstruction, malabsorption).

          -  Has known hypersensitivity or allergy to the active pharmaceutical ingredient or any
             component of the study intervention (MK-6482 or everolimus) formulations.

          -  Has received prior treatment with MK-6482 or another hypoxia inducible factor 2α
             (HIF-2α inhibitor).

          -  Has received prior treatment with everolimus or any other specific or selective target
             of rapamycin complex 1 (TORC1)/ phosphatidylinositol 3-kinase (PI3K)/ protein kinase B
             (AKT) inhibitor (e.g., temsirolimus) in the advanced disease setting.

          -  Has received any type of systemic anticancer antibody (including investigational
             antibody) within 4 weeks before randomization.

          -  Has received prior radiotherapy within 2 weeks prior to randomization.

          -  Has had major surgery within 3 weeks prior to randomization.

          -  Has received a live vaccine within 30 days prior to randomization. Examples of live
             vaccines include, but are not limited to, the following: measles, mumps, rubella,
             varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG),
             and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed
             virus vaccines and are allowed; however, intranasal influenza vaccines are live
             attenuated vaccines and are not allowed.

          -  Is currently receiving either strong (e.g., itraconazole, telithromycin,
             clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir,
             saquinavir, nelfinavir, boceprevir, telaprevir) or moderate (e.g., ciprofloxacin,
             erythromycin, diltiazem, fluconazole, verapamil) inhibitors of cytochrome P450 3A4
             (CYP3A4) that cannot be discontinued for the duration of the study.

          -  Is currently receiving either strong (phenobarbital, enzalutamide, phenytoin,
             rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or
             moderate (e.g., bosentan, efavirenz, modafinil) inducers of CYP3A4 that cannot be
             discontinued for the duration of the study.

          -  Is currently participating in a study of an investigational agent or is currently
             using an investigational device.

          -  Has an active infection requiring systemic therapy.

          -  Has active bacillus tuberculosis (TB).

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             (dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days prior to randomization.

          -  Has a known history of human immunodeficiency virus (HIV) infection. (Testing for HIV
             at screening is only required if mandated by local health authority.

          -  Has a known history of Hepatitis B virus (HBV) (defined as Hepatitis B surface antigen
             [HBsAg] reactive) or known active Hepatitis C virus (HCV) (defined as HCV ribonucleic
             acid [RNA] [qualitative] is detected) infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Joseph Heritage Healthcare ( Site 1531)</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>707-521-3830</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Colorado ( Site 1540)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>720-848-1776</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCHealth Highlands Ranch Hospital ( Site 1560)</name>
      <address>
        <city>Highlands Ranch</city>
        <state>Colorado</state>
        <zip>80129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>720-848-1776</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers PC ( Site 1520)</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>770-333-2161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center ( Site 1539)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>773-702-3498</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute ( Site 1505)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>877-338-7425</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Cancer Center ( Site 1511)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-916-8862</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic ( Site 1509)</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>601-288-2495</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent Frontier Cancer Center ( Site 1549)</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>406-238-6290</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center ( Site 1543)</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>585-276-4415</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill ( Site 1537)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>28512</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>919-966-4432</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care, Inc. ( Site 1524)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>513-751-2273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1523)</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>918-505-3200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University ( Site 1553)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>503-494-0703</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center ( Site 1525)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>267-581-6080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center ( Site 1506)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-728-3889</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Joyce Cancer Clinic ( Site 1544)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>800-811-8480</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sociedad de Investigaciones Medicas Limitadas ( Site 0004)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4810469</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>56452982404</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sociedad Medica Aren y Bachero Limitada ( Site 0003)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>8420383</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56954240753</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Centro de Investigacion Clinica CIC ( Site 1703)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050021</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>573137431031</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Administradora Country SA - Clinica del Country ( Site 1701)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573153679697</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 1702)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>110311</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573103469453</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncologos del Occidente S.A. ( Site 1708)</name>
      <address>
        <city>Pereira</city>
        <state>Risaralda</state>
        <zip>660001</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573187715522</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital ( Site 0251)</name>
      <address>
        <city>Herlev</city>
        <state>Hovedstaden</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4538683868</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital Skejby ( Site 0250)</name>
      <address>
        <city>Aarhus</city>
        <state>Midtjylland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4578450000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopistollinen sairaala ( Site 0300)</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358331163454</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kuopion Yliopistollinen Sairaala ( Site 0304)</name>
      <address>
        <city>Kuopio</city>
        <state>Pohjois-Savo</state>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358 44 717 9433</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HYKS. ( Site 0302)</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358504279697</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>TYKS T-sairaala Syopatautien pkl ( Site 0301)</name>
      <address>
        <city>Turku</city>
        <state>Varsinais-Suomi</state>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35823130729</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy ( Site 0353)</name>
      <address>
        <city>Villejuif</city>
        <state>Val-de-Marne</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142115252</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital ( Site 1051)</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+85222556220</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz ( Site 0502)</name>
      <address>
        <city>Miskolc</city>
        <state>Borsod-Abauj-Zemplen</state>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36302780644</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri IRCCS ( Site 0600)</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390382592265</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli ( Site 0607)</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390630154953</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria di Verona ( Site 0605)</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390458122768</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center ( Site 1204)</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>Kyonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82319201505</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital ( Site 1203)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8229206267</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 1202)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222288138</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center ( Site 1200)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82230105977</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 1201)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82234101767</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital ( Site 1205)</name>
      <address>
        <city>Daejeon</city>
        <state>Taejon-Kwangyokshi</state>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82422808369</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akershus universitetssykehus ( Site 0851)</name>
      <address>
        <city>Lorenskog</city>
        <state>Akershus</state>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4767963800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helse Bergen HF - Haukeland Universitetssykehus ( Site 0854)</name>
      <address>
        <city>Bergen</city>
        <state>Hordaland</state>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4755974018</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SBIH City clinical hospital named after D.D. Pletniov ( Site 1160)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>105077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79164091611</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>N.N. Blokhin NMRCO ( Site 1156)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79037380779</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital with Polyclinic ( Site 1157)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>121359</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79031691379</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d Hebron ( Site 1250)</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34934894350</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Catalan de Oncologia - ICO ( Site 1251)</name>
      <address>
        <city>L Hospitalet De Llobregat</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932607744</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncologia - IVO ( Site 1254)</name>
      <address>
        <city>Valencia</city>
        <state>Valenciana, Comunitat</state>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34961104605</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal ( Site 1253)</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913368263</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario 12 de Octubre ( Site 1252)</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913908339</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital ( Site 1103)</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88662353535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital ( Site 1100)</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>88623123456x67680</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital ( Site 1101)</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>886228757519x315</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trakya University Medical Faculty Balkan Oncology Hospital ( Site 1302)</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905322480988</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medeniyet Universitesi Goztepe Egitim ve Arastirma Hastanesi ( Site 1303)</name>
      <address>
        <city>Istanbul</city>
        <zip>34732</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905063509061</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MI Dnipr Regional Clinical Hospital named after I.I. Mechnikov ( Site 1453)</name>
      <address>
        <city>Dnipropetrovsk</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380505896241</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MI Precarpathian Clinical Oncology Center ( Site 1452)</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <state>Ivano-Frankivska Oblast</state>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380502094000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Oncology Center ( Site 1450)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380667027558</phone>
    </contact>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Norway</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoxia inducible Factor (HIF)</keyword>
  <keyword>Hypoxia inducible factor 1B (HIF-1B)</keyword>
  <keyword>Hypoxia inducible factor 2 alpha (HIF-2 alpha)</keyword>
  <keyword>Hypoxia inducible factor 2α (HIF-2α)</keyword>
  <keyword>Renal Cell Carcinoma (RCC)</keyword>
  <keyword>Kidney Cancer</keyword>
  <keyword>PT-2977</keyword>
  <keyword>PT2977</keyword>
  <keyword>MK6482</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

